Iqwig Early Benefit Assessments of Type 2 Diabetes Therapies

Value in Health - United Kingdom
doi 10.1016/j.jval.2015.03.060
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Can Routine Data Be Used to Determine the Target Population of Patients With Type 2 Diabetes in Early Benefit Assessments in Germany?

Gesundheitswesen
MedicineEnvironmentalPublic HealthOccupational Health
2019English

Adipositas Bei Typ-2-Diabetes – IQWiG: Vorbericht Zu Recherche

Diabetes Aktuell
Internal MedicineEndocrinologyMetabolismDiabetes
2011English

Comparison of Efficacy Between Incretin-Based Therapies for Type 2 Diabetes Mellitus

BMC Medicine
Medicine
2012English

Inclusion and Consideration of Patient Preferences in Amnog Early Benefit Assessments

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Comparison of Iqwig and G-Ba Benefit Ratings in Oncology

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Php287 - German Early Benefit Assessments of Orphan Drugs Under Full Dossier Conditions

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pcn315 - Impact of Pro Data on Iqwig Benefit Ratings in Oncology

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Incorporating Incretin-Based Therapies Into Clinical Practice for Patients With Type 2 Diabetes

Advances in Therapy
MedicinePharmacology
2014English

Early Puberty and Risk for Type 2 Diabetes in Men

Diabetologia
Internal MedicineEndocrinologyMetabolismDiabetes
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy